Mivazerol

From Food & Medicine Encyclopedia

Mivazerol is a drug that was developed for the treatment of ischemic heart disease. It is a selective alpha 2 adrenergic agonist.

Pharmacology[edit]

Mivazerol works by stimulating alpha 2 adrenergic receptors, which are found in the heart and blood vessels. This stimulation leads to a decrease in heart rate and blood pressure, which can be beneficial in the treatment of ischemic heart disease.

Clinical Trials[edit]

Mivazerol has been tested in several clinical trials. In one study, it was found to reduce the incidence of myocardial infarction (heart attack) in patients undergoing non-cardiac surgery. However, in another study, it did not show a significant benefit in reducing the risk of death or heart attack in patients with stable angina.

Side Effects[edit]

The most common side effects of mivazerol include dizziness, headache, and nausea. Less common side effects include bradycardia (slow heart rate), hypotension (low blood pressure), and dry mouth.

Development and Approval[edit]

Mivazerol was developed by Hoffmann-La Roche, a Swiss multinational healthcare company. However, it has not been approved for use by the Food and Drug Administration (FDA) in the United States.

See Also[edit]

Stub icon

This medical article is a stub. You can help WikiMD by expanding the page.

  • Mivazerol
    Mivazerol

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Mivazerol&oldid=6416137"